Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


17.05.24 / Tradegate WKN: 920657 / Name: Snof / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Sanofi S.A. Stock

Our community is currently high on Sanofi S.A. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 99 € shows a slightly positive potential of 10.16% compared to the current price of 89.87 € for Sanofi S.A..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Sanofi S.A. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Sanofi S.A. in the next few years

W********* I********* f** t** n*** y****
G***** c******* t* c**********
M***** P*******
C******** o* t** e**********
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sanofi S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sanofi S.A. -0.100% -4.869% 3.968% -9.268% 0.134% 1.824% 19.827%
Ipsen S.A. 0.170% 0.833% 13.829% 7.556% 12.873% 43.637% 11.418%
Elanco Animal Health Inc. -0.140% 0.241% 25.803% 101.221% 16.982% -45.102% -
Pfizer Inc. -1.240% 1.307% 10.668% -22.386% 0.958% -20.139% -25.362%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon first glance at the financial statements of Snof, a pharmaceutical company, it appears that the company has experienced growth in key financial metrics such as total assets, total revenue, and net income. Over the recent years, the company has demonstrated a consistent increase in these indicators, reflecting positively on its financial health.

Growth in Total Assets: The total assets of Snof have grown consistently over the past three years, from €114.53 billion in 2020 to €120.24 billion in 2021, and eventually to €124.58 billion in 2022. This growth signifies that the company is expanding and successfully acquiring more resources to fuel its operations.

Increasing Revenue: Snof's total revenue has been on an upward trajectory, as evidenced by its growth from €37.37 billion in 2020 to €39.18 billion in 2021 and €45.39 billion in 2022. This demonstrates the company's ability to generate higher sales, which is essential for sustaining its growth trajectory.


Prediction Buy
Perf. (%) 1.76%
Target price 95.000
Ends at 06.02.23

Buy with target price 95.0
Show more

Prediction Buy
Perf. (%) 20.12%
Target price 89.000
Ends at 14.09.22

Buy with target price 89.0
Show more

Prediction Sell
Perf. (%) 9.12%
Target price
Ends at 20.12.19

Sell beendet
Show more